Modality
Gene Therapy
MOA
SOS1i
Target
WEE1
Pathway
PD-1/PD-L1
RettT2DSchizophrenia
Development Pipeline
Preclinical
~Dec 2015
→ ~Mar 2017
Phase 1
~Jun 2017
→ ~Sep 2018
Phase 2
~Dec 2018
→ ~Mar 2020
Phase 3
~Jun 2020
→ ~Sep 2021
NDA/BLA
Dec 2021
→ May 2031
NDA/BLACurrent
NCT06091607
1,523 pts·Rett
2021-12→2031-05·Not yet recruiting
1,523 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-05-185.1y awayPh3 Readout· Rett
Trial Timeline
Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3
NDA/BLA
Not yet…
Catalysts
Ph3 Readout
2031-05-18 · 5.1y away
Rett
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06091607 | NDA/BLA | Rett | Not yet recr... | 1523 | UPDRS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2901 | Pfizer | Phase 2 | AHR | |
| MRK-1380 | Merck & Co | Preclinical | SHP2 | |
| Terarelsin | AbbVie | Preclinical | SOS1 | |
| Doxarapivir | Bristol-Myers Squibb | Phase 3 | KRASG12C | |
| TAK-2403 | Takeda | Phase 2 | WEE1 | |
| DSN-6862 | Daiichi Sankyo | Preclinical | IL-23 | |
| Sovacapivasertib | Amgen | Phase 3 | WEE1 | |
| GIL-2011 | Gilead Sciences | Preclinical | VEGF | |
| REG-647 | Regeneron | Preclinical | SMN2 | |
| Cevisacituzumab | Alnylam | Preclinical | MALT1 |